Outlier [Study As­sess­ment]

posted by NK – India, 2023-06-27 05:57 (696 d 16:32 ago) – Posting: # 23616
Views: 3,107

Dear All,

Please give your valuable inputs.

We have performed 2x2 fasting BE pivotal study for USFDA after seeing pilot study results.

We've noted following from pivotal study data,How to handle this subject’s data? Outlier? Can the regulatory accept the based on Cmax and AUC0-t results?

Can we select the time point manually for Kel calculation instead of best fit method by the tool?

Thanks & Regards
NK


Edit: Category changed; see also this post #1[Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,683 registered users;
52 visitors (0 registered, 52 guests [including 23 identified bots]).
Forum time: 22:30 CEST (Europe/Vienna)

Pharmacokinetics may be simply defined as
what the body does to the drug,
as opposed to pharmacodynamics, which may be defined as
what the drug does to the body.    Leslie Z. Benet

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5